MrG,
Dividend Data do not list a forthcoming divi yet. I checked for the next year's dates just after the last divi was paid.
If I remember correctly, it was announced early May for payment towards the end of the month.
I'll be asking IG to receive my divi in £s and will report back if they flag issues doing so.
FD,
Apologies fior not making it clear that any fund raise would take RM over the amount where they would have to make an offer at a ~15p eg the raise price.
The sooner we get to Vulpes ~50p/share valuation the better in my humble view. Then their analysts will need to do some work quantifying various scenarios to show the value ranges of Scancell's IP. Presumably this will happen after the next release of news via an RNS.
GL all!
All I recall skimming Vulpes report on my phone was that they consider the current share price to be 62% undervalued. I took this to mean that they feel the share price should already be at about 50p / share (19/.38).
As others noted, I felt this was a huge flag to the lineup of the hedge fund/pharma beauty contestants to think hard about their offer price or swap package.
I think someone mentioned RM have not paid more than 13p/share and therefore could offer that for all shares.
I think I also think I've heard a few say that Scancell may need to raise funds at some point this year/next year at around 15.
GLA - great to see the robust and collegiate discussions.
LL
And now the huge spread is gone.
Not sure what this means, but thought someone might
This came across my feed - thought a few might be interested
USA have a $5BN program to fund therapies and nasal and variant-proof Covid vaccines.
https://www.washingtonpost.com/health/2023/04/10/operation-warp-speed-successor-project-nextgen/
Johnny, Thanks for posting this. This along with all the evidence pouring in about mortality findings may just put the need for a viable solution back on the table (not withstanding the millions of immunosuppressed who have no vaccine).
[My strong buy personal opinion is without/outwith the prospect of a covid vaccine funding/manufacture - the market for a melanoma solution alone around the globe is ~$5.64 billion by 2023 and will grow from there, even if the population shrinks.
[https://www.europeanpharmaceuticalreview.com/news/30781/melanoma-treatment-market-value-to-more-than-quadruple-to-5-64-billion-by-2023-reports-globaldata/]
Good Luck All, LL
[After glimmers of spring, there was snow back on the tops of the hills here, though it was warmer at sea level. Lovely to see a couple of starfish (live) in the water from a safe, dry spot on the pontoon.]
In case you missed it.
I assume that this runs across all trading platforms - end of firms taking out a little bit extra....
https://ir.div.energy/dividend-information
Def90
Think this CRO is contract research organisation (CRO) provides research services – such as assay development or drug discovery – on a contractual basis. Pharmaceutical and biotechnology companies may outsource work to a CRO in order to reduce costs and complete tasks that they wouldn't be able to do 'in house'.
My knowledge very different- eg Chief Risk Officer
Divi paid at 3p / share so small top up.
I have mine in an ISA
When I thought I would need the SIPP, the internet said that you could claim 25% off regular payments. If you hold off claiming the pensions for the first year, it gives you the personal allowance to play with, so you could withdraw enough to top up the ISA with a nominal tax charge.
Or you could cash out to the highest 20% tax level and set the rump up in a share trading account as it would not breach the divi tax allowance next year (£1k). Should you breach the CG allowance (£6k) for the year, you could keep the rump in the share trading account for the following year and move it to the ISA the following year.
You also collect the uplift on your pension for the following years (just under 6% for a full year, I think it is 1% for every 9 week delay in starting it). My plan was to hold off the state pension until I emptied the SIPP entirely, cashing out to the max 20% tax band plus the tax free 25%. This would have given an uplift of about 15% on the state pension.
I think it is worth considering the options. Obviously many are keen that worthy vaccines/protocols get to patients as quickly as possible.
IDK what all the options are, so I'll wait to hear from the experts as to views.
Me too, I managed to puck up some. Now up to about 10% of my holdu gs last year.
I found yesterday that my platform would not fill limit orders even though the rates appeared to be higher (looking historically).
My way around it was to request a quote order, and not execute. Then i issued a fixed price for the level quoted for the max shares. That rate was lower than the limit orders I had filed earlier.
This also avoided the small £ rump which I cannot trade without topping up.
TF, I hope Scancell (and others) benefit from these measures, at least financially.
I don't see a fast track, merely UK reliance on other countries to do the DD and clearance.
I'm a bit concerned that this puts these 20k strong small firms at a serious disadvantage as it means they would need to get Reg. Approval elsewhere. Cost of running offshore CTs, putting UK patients at the back of the queue for cutting edge CTs, etc.
Ideas anyone?
Ukvrkw, how do you avoid tax on the withdrawal.
Yes you can take 25% tax free. However, even the basic state pension is within spitting distance of the 20% tax band.
Until I again have more than £20k disposal income pa to invest, I'll be sticking with ISAs.
Hi all, it's been a busy week. I've just been reading about Wind Farm REITs as a tangent to an article I've submitted.
Anyone here have views?
Agree that an ISA is the best place to hold them due to tax implications, provided there is an attractive entrant.
Absolutely agree with this.
Some here will remember my long term view that a communications officer is essential. I also understand the need to conserve the cash, but it is more than just a "when someone gets around to it" when they have a spare 10 minutes every other month. Tomorrow would be a better day to garner interest unless the can link their efforts to today's anniversary.
But hey, it is Friday, perhaps someone from Scancell may take 5 minutes to read this board and recognise the need. I've just finished one research assignment early and am moving on to a few articles I want to write - after I stretch my legs because it is Friday, and it is glorious outside spotting signs of spring.
Rich, Thank you for that - I am just going into another meeting an your post reminded me that there is an abundance of value in the proprietary tech Scancell have developed. Plus they have brought in a key player who will want to be making his mark.
C7 - good to see you posting today, I trust all is as well or better than it possibly could be.
ATB All, LL
Ruck, I have not kept up with significant holdings, but I thought Redmile were at the cusp of having to make an offer if they increased their shareholding further.
I don't have time to look it up as I'm right in the middle of a project. I'm just stealing a minute away.
Can't spot a post quickly that points the way. If someone has the time, grateful thanks.
For all: As for the efficacy of the trial, these patients were all very poorly. I didn't expect "miracles all round", I think it is extremely positive that none got "worse"/passed away.
The bit about week 8 consclusions
"Of these patients, one has had a confirmed partial response and seven patients have stable disease, despite having progressive disease prior to enrolment in the study. As no dose limiting toxicities were observed in the monotherapy dose escalation cohorts, patients continue to be enrolled into both the ongoing monotherapy expansion cohorts and the CPI combination dose escalation cohorts during H1 2023."
The fact that they have been stable for two months is worth celebrating.
I believe I'm realistic about LD's comments and expect to see patients stable / improving with their plans.
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "We are highly encouraged with the early efficacy data we have achieved in the ModiFY clinical trial, and safety profile to date with patients receiving Modi-1. These results allow us to proceed with the monotherapy expansion cohorts and into the cohorts in combination with checkpoint inhibitors as planned."
Great stuff. I'm just finishing up for the evening, and now I might be hard to get to sleep (ask me if I care)
GLA, LL